Actively Recruiting
Evaluating the Impact of Beta-blocker Use in Adults Undergoing Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis
Led by University Hospital, Basel, Switzerland · Updated on 2025-11-28
498
Participants Needed
11
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Aortic stenosis AS is a common heart valve problem in older adults, leading to serious symptoms and increased health risks. Transcatheter Aortic Valve Replacement TAVR is a recognized treatment for severe AS, especially for those at high risk with traditional surgery. Many patients with AS also take beta-blockers to manage related heart conditions, but these medications may increase the risk of needing a pacemaker after TAVR due to their effects on heart rhythm. This trial compares two approaches to beta-blocker use in patients undergoing TAVR one group pauses beta-blockers 72 hours before the procedure and resumes them 72 hours after, while the other group continues beta-blockers throughout. The study is open-label and randomized, involving multiple centers, and aims to assess the safety and impact of temporarily stopping beta-blockers around the time of TAVR. Participants will be monitored for outcomes including mortality, rehospitalization due to heart failure, stroke, and severe arrhythmias at 30 days, with additional follow-up for pacemaker implantation and other events up to one year. Researchers will evaluate these measures to understand the effects of beta-blocker management during TAVR, with the overall study lasting until May 2028.
CONDITIONS
Brief Title
Impact of Beta-blocker on Outcome Among Patients Undergoing Transcatheter Aortic Valve Replacement (B-TAVR)
Research Team
N
Nicole Gilgen, Dr. med.
T
Thomas Nestelberger, PD Dr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here